1-2 of 2
Leena Gandhi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, John F. Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martinez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (7): 740–753.
https://doi.org/10.1158/2159-8290.CD-16-0095
Published: 30 June 2016
View article titled, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Open the PDF for Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Nikhil Wagle, Brian C. Grabiner, Eliezer M. Van Allen, Eran Hodis, Susanna Jacobus, Jeffrey G. Supko, Michelle Stewart, Toni K. Choueiri, Leena Gandhi, James M. Cleary, Aymen A. Elfiky, Mary Ellen Taplin, Edward C. Stack, Sabina Signoretti, Massimo Loda, Geoffrey I. Shapiro, David M. Sabatini, Eric S. Lander, Stacey B. Gabriel, Philip W. Kantoff, Levi A. Garraway, Jonathan E. Rosenberg
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2014) 4 (5): 546–553.
https://doi.org/10.1158/2159-8290.CD-13-0353
Published: 01 May 2014
View article titled, Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Open the PDF for Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib in another window
Includes: Supplementary data